John Eric Levine MD

Professor, Pediatrics
Pediatric Hematology/Oncology, Pediatrics
Clinical Interests:

Bone marrow/stem cell transplantation.

Video profile


U of M Pediatric Hematology Oncology

CS Mott Children's Hospital
1540 E Hospital Dr, Level 7, Reception B and C
Ann Arbor


Medical School or Training

  • Eastern Virginia Medical School, 1989


  • Children's Hospital of Los Angeles, Pediatrics, CA, 1992


  • Pediatric Hematology/Oncology, Memorial Sloan-Kettering Cancer Center, 1995

Board Certification

  • Pediatric Hematology-Oncology


Dr. Levine collaborates with other BMT Program members in the study of graft-versus-host disease, the major complication of allogeneic bone marrow transplantation. He is an author of over 75 medical papers and 7 book chapters and has risen to international prominence in his field. Dr. Levine helps guide national research projects and holds leadership positions for the Children’s Oncology Group, the Blood and Marrow Transplant Clinical Trials Network, the Pediatric Blood and Marrow Transplantation Consortium, the National Marrow Donor Program, and the Center for International Blood and Marrow Transplantation Research.

Recent Publications:

  1. Levine JE, Paczesny S, Sarantopoulos S. Clinical applications for biomarkers of acute and chronic graft-versus-host disease. Biol Blood and Marrow Transplant, 18:S116-24, 2012.
  2. Levine JE, Logan BR, Wu J, Alousi AM, Bolaños Meade J, Ferrara JLM, Ho VT, Weisdorf DJ, Paczesny S. Acute graft-versus-host disease biomarkers measured during therapy can predict treatment outcomes: A Blood and Marrow Transplant Clinical Trials Network study. Blood, 119:3854-60, 2012.
  3. Choi SW, Stiff P, Cooke K, Ferrara JLM, Braun T, Kitko C, Reddy P, Yanik G, Mineishi S, Paczesny S, Hanauer D, Pawarode A, Peres E, Rodriguez T, Smith S, Levine JE. TNF-inhibition with etanercept for graft versus host disease prevention in high risk HCT: Lower TNFR1 levels correlate with better outcome. Biol Blood Marrow Transplant, 18:1525-32, 2012.
  4. Levine JE, Huber E, Hammer ST, Harris AC, Greenson JK, Braun TM, Ferrara JL, Holler E. Low Paneth cell numbers at onset of gastrointestinal graft-versus-host disease identify patients at high risk for nonrelapse mortality. Blood. 122(8):1505-9, 2013.
  5. Vander Lugt MT, Braun TM, Hanash S, Ritz J, Ho VT, Antin JH, Zhang Q, Wong CH, Wang H, Chin A, Gomez A, Harris AC, Levine JE, Choi SW, Couriel D, Reddy P, Ferrara JL, Paczesny S. ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death. N Engl J Med, 8;369(6):529-39, 2013.


Dr. John Levine, the Clinical Director of the Pediatric Blood and Marrow Transplantation Program, received his undergraduate degree in Biochemistry from the University of Virginia and a medical degree from Eastern Virginia Medical School. Following a three-year residency in pediatrics at Children's Hospital of Los Angeles, he completed a pediatric hematology/oncology fellowship at Memorial Sloan-Kettering Cancer Center in New York City.   He has been a member of the University of Michigan faculty since 1995, first in the Department of Pediatrics and then receiving a joint appointment in the Department of Internal Medicine in 2005. Dr. Levine was awarded a master's degree in clinical trial design and statistical analysis by the U-M School of Public Health in 2003. He and his wife have raised their four sons in Ann Arbor. He enjoys camping, backpacking, and attending sporting events, especially University of Michigan football and Detroit Tigers baseball games.